DepYmed, Inc.
www.depymed.comDepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases. In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer.
Read more
DepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases. In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer.
Read more
Country
State
New York
Industry
Employees
1-10
Founded
2014
Social
Employees statistics
View all employeesPotential Decision Makers
Senior Vice President of Early Development
Email ****** @****.comPhone (***) ****-****President and Chief Executive Officer
Email ****** @****.comPhone (***) ****-****
Reach decision makers at DepYmed, Inc.
Free credits every month!
DepYmed, Inc. FAQ
United States
Biotechnology Research
